GLP-1 treatment can also positively impact people with poor control of their blood sugar, blood pressure, and/or cholesterol levels, contributing to improved long-term health outcomes
It is generally not seen for Tirzepatide or Retatrutide in standard metabolic research, as their long-acting nature makes daily administration unnecessary and potentially counterproductive due to accumulation
Many patients experience rapid initial loss (weeks 2-8), a plateau phase (weeks 8-16), then resumption of gradual loss as tolerance stabilizes
You may not be able to control every menstrual fluctuation, but you can support your body through the transition period
pharmaceutical company Eli Lilly recently launched a platform (dubbed Employer Connect) to close the gap for patients who have started or are seeking treatment but cant afford the drug costs, which typically top $1,000 per month
Published on October 23rd, 2025